One study reported Hic-5 to become expressed in prostate cancer epithelial cells after ADT therapy (Li et al. 2011), and Hic-5 is also expressed in AR null-PC3 cells (in which exogenous AR signalling resembles fibroblast AR signalling) (Litvinov et al. 2006, Kim et al. 2015, Leach et al. 2015); perhaps, as an attempt by the cancer cells to become less epithelial, or more mesenchymal, and escape the effects of ADT treatment. The gene discussed is TGFB1I1; the disease is prostate carcinoma.